SRD-097

SRD-097 is an investigational gene therapy currently in preclinical development by Sardocor for the treatment of chronic ischemia. As a key component of Sardocor's vascular program, SRD-097 is designed to address conditions characterized by persistent restricted blood flow to tissues. While Sardocor's primary technological focus involves the use of adeno-associated virus (AAV) vectors to deliver therapeutic genes—most notably the SERCA2a gene in its cardiac programs—the specific genetic target and vector for SRD-097 have not been publicly disclosed. The therapy aims to leverage gene transfer technology to restore vascular function or promote tissue revascularization in patients suffering from ischemic diseases.